Drug name - Trijardy Xr
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(2 years from now) | |
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(4 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(5 years from now) | |
| CN1930141A | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
May, 2014
(8 years ago) | |
| CN103450129A | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
May, 2021
(1 year, 4 months ago) | |
| CN103450129B | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
May, 2021
(1 year, 4 months ago) | |
| CN103435581B | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same |
Sep, 2021
(1 year, 25 days ago) | |
| CN103467423B | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
Sep, 2021
(1 year, 25 days ago) | |
| CN103467423A | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
Sep, 2021
(1 year, 25 days ago) | |
| CN103435581A | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
Sep, 2021
(1 year, 25 days ago) | |
| CN101503408B | BOEHRINGER INGELHEIM | 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds |
Aug, 2023
(10 months from now) | |
| CN1675212A | BOEHRINGER INGELHEIM | 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation |
Aug, 2023
(10 months from now) | |
| CN105001222B | BOEHRINGER INGELHEIM | 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation |
Aug, 2023
(10 months from now) | |
| CN100522962C | BOEHRINGER INGELHEIM | 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation |
Aug, 2023
(10 months from now) | |
| CN101503408A | BOEHRINGER INGELHEIM | 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound |
Aug, 2023
(10 months from now) | |
| CN101503409A | BOEHRINGER INGELHEIM | 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2023
(10 months from now) | |
| CN102964347B | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament |
Aug, 2023
(10 months from now) | |
| CN102964347A | BOEHRINGER INGELHEIM | 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation |
Aug, 2023
(10 months from now) | |
| CN101503409B | BOEHRINGER INGELHEIM | 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations |
Aug, 2023
(10 months from now) | |
| CN105001222A | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament |
Aug, 2023
(10 months from now) | |
| CN101155794B | BOEHRINGER INGELHEIM | 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine |
May, 2026
(3 years from now) | |
| CN101155794A | BOEHRINGER INGELHEIM | Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments |
May, 2026
(3 years from now) | |
| IN200500567P1 | BOEHRINGER INGELHEIM | 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds |
Aug, 2023
(10 months from now) | |
| IN243301B | BOEHRINGER INGELHEIM | 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds |
Aug, 2023
(10 months from now) | |
| IN200604844P1 | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
Mar, 2025
(2 years from now) | |
| IN268846B | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof |
Mar, 2025
(2 years from now) | |
| EP1828216B1 | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture |
Dec, 2025
(3 years from now) | |
| EP1828216A2 | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture |
Dec, 2025
(3 years from now) | |
| EP1888552A1 | BOEHRINGER INGELHEIM | Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments |
May, 2026
(3 years from now) | |
| EP1888552B1 | BOEHRINGER INGELHEIM | Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments |
May, 2026
(3 years from now) | |
| EP1532149B9 | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2026
(3 years from now) | |
| EP1532149A2 | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2026
(3 years from now) | |
| EP1532149B1 | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2026
(3 years from now) | |
| EP1730131B1 | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
May, 2029
(6 years from now) | |
| EP1730131A1 | BOEHRINGER INGELHEIM | Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof |
May, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(10 months from now) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(6 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(6 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(7 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(7 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(7 years from now) | |
| US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprising linagliptin, metformin, empagliflozin and a basic amino acid; Method of treating type 2 diabetes mellitus using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Method of treating a type 2 diabetes mellitus patient with insufficient glycemic control despite therapy with metformin using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG;2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 10MG;5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 12.5MG;2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 25MG;5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.